Circulating Cytokines Predict the Development of Insulin Resistance in a Prospective Finnish Population Cohort.
暂无分享,去创建一个
O. Raitakari | T. Pahikkala | S. Jalkanen | A. Airola | M. Salmi | N. Hutri-Kähönen | K. Santalahti | M. Maksimow
[1] M. Donath. Targeting inflammation in the treatment of type 2 diabetes: time to start , 2014, Nature Reviews Drug Discovery.
[2] Zhenwen Zhang,et al. Endogenous peptides as risk markers to assess the development of insulin resistance , 2014, Peptides.
[3] Kassem M. Makki,et al. Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines , 2013, ISRN inflammation.
[4] Aleksandar Pantovic,et al. Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels. , 2013, Immunobiology.
[5] I. Jialal,et al. Adipose Tissue Dysfunction in Nascent Metabolic Syndrome , 2013, Journal of obesity.
[6] J. Viikari,et al. Main findings from the prospective Cardiovascular Risk in Young Finns Study , 2013, Current opinion in lipidology.
[7] J. Olefsky,et al. The cellular and signaling networks linking the immune system and metabolism in disease , 2012, Nature Medicine.
[8] J. Higaki,et al. Roles of Interleukin 17 in Angiotensin II Type 1 Receptor–Mediated Insulin Resistance , 2012, Hypertension.
[9] Wen-bin Liu,et al. Estrogen Suppresses Metastasis in Rat Hepatocellular Carcinoma through Decreasing Interleukin-6 and Hepatocyte Growth Factor Expression , 2012, Inflammation.
[10] H. Roche,et al. Lack of Interleukin-1 Receptor I (IL-1RI) Protects Mice From High-Fat Diet–Induced Adipose Tissue Inflammation Coincident With Improved Glucose Homeostasis , 2011, Diabetes.
[11] V. Mohan,et al. Decreased serum interleukin-17 and increased transforming growth factor-β levels in subjects with metabolic syndrome (Chennai Urban Rural Epidemiology Study-95). , 2011, Metabolism: clinical and experimental.
[12] S. Shoelson,et al. Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.
[13] C. Apovian,et al. Elevated Proinflammatory Cytokine Production by a Skewed T Cell Compartment Requires Monocytes and Promotes Inflammation in Type 2 Diabetes , 2011, The Journal of Immunology.
[14] E. Butcher,et al. IL-17 Regulates Adipogenesis, Glucose Homeostasis, and Obesity , 2010, The Journal of Immunology.
[15] D. Khan,et al. Estrogen increases, whereas IL‐27 and IFN‐γ decrease, splenocyte IL‐17 production in WT mice , 2010, European journal of immunology.
[16] A. Vaag,et al. Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes , 2009, Diabetes Care.
[17] Risto Telama,et al. Cohort profile: the cardiovascular risk in Young Finns Study. , 2008, International journal of epidemiology.
[18] Allan Vaag,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.
[19] S. Kahn,et al. Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.
[20] A. Goldfine,et al. Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.
[21] L. Bernstein,et al. Effects of etanercept in patients with the metabolic syndrome. , 2006, Archives of internal medicine.
[22] Tom R. Gaunt,et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study , 2005, The Lancet.
[23] Yuichiro Yamada,et al. C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients. , 2002, Metabolism: clinical and experimental.
[24] Roger Davis,et al. The c-Jun NH2-terminal Kinase Promotes Insulin Resistance during Association with Insulin Receptor Substrate-1 and Phosphorylation of Ser307 * , 2000, The Journal of Biological Chemistry.
[25] A. Scheen,et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. , 2000, The Journal of clinical endocrinology and metabolism.
[26] E. Ford. Body mass index, diabetes, and C-reactive protein among U.S. adults. , 1999, Diabetes care.
[27] K. Uysal,et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.
[28] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[29] M. Colonna,et al. Accepted Manuscript Association Between Specific Adipose Tissue CD 4 + T-Cell Populations and Insulin Resistance in Obese People , 2013 .
[30] G. Pacini,et al. Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome , 2011, Molecular medicine.
[31] T. Sasaoka,et al. Interleukin-1α inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes , 2006 .
[32] E. Bonora,et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.